Proton Pump Inhibitor Use in Patients With Cirrhosis and Its Association With Spontaneous Bacterial Peritonitis
- 22 August 2025
- journal article
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 41 (6) , 283-290
Abstract
Background: Cirrhosis is a major cause of morbidity and mortality in the United States, with spontaneous bacterial peritonitis (SBP) being a serious complication. Established SBP risk factors include gastrointestinal bleeding and low ascitic protein, but the role of proton pump inhibitors (PPIs) remains unclear. Objective: This study evaluated the impact of PPI use on primary SBP development in hospitalized patients with cirrhosis. Additional objectives included reviewing PPI prescribing patterns and associated clinical outcomes. Methods: An institutional review board–approved, retrospective chart review was conducted on adults (≥18 years) with cirrhosis admitted for presumed SBP between June 1, 2022, and June 30, 2024. Exclusion criteria included pregnancy, incarceration, and recent or current upper gastrointestinal bleeding. Patients were grouped by PPI exposure, defined as PPI use prior to admission. The primary outcome was SBP incidence; secondary outcomes included mortality and hepatic decompensation events. Results: Eighty-one patients were included: 42 reported home PPI therapy, and 39 did not. SBP incidence was 33.3% in the PPI group versus 20.5% in the no PPI group (χ 2 = 0.249, P = 0.618). Worsening ascites occurred in 99%, encephalopathy in 42%, varices in 11%, and suspected hepatorenal syndrome in 21%. In-hospital mortality was 9.9%. PPI indications were often undocumented. Conclusion and Relevance: Although no significant association was found between home PPI use and SBP, frequent undocumented use and potential overuse of PPIs underscore the need for targeted intervention. Pharmacists are well-positioned to lead stewardship efforts by reviewing indications and minimizing unnecessary therapy to enhance safety and outcomes.Keywords
This publication has 27 references indexed in Scilit:
- Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-AnalysisDigestive Diseases and Sciences, 2023
- The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort StudyGastroenterology, 2022
- AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert ReviewGastroenterology, 2022
- Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2021
- Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascitesHepatology, 2016
- Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosisEuropean Journal of Internal Medicine, 2016
- Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysisDigestive and Liver Disease, 2016
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Small Intestine Dysmotility and Bacterial Overgrowth in Cirrhotic Patients With Spontaneous Bacterial PeritonitisHepatology, 1998
- Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascitesGastroenterology, 1995